Sep 24 |
Surrozen earns $10M milestone payment through Boehringer collaboration
|
Sep 24 |
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
|
Aug 15 |
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky
|
Aug 13 |
Surrozen GAAP EPS of -$7.99
|
Aug 12 |
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
|
Jun 12 |
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
|
Jun 10 |
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
|
Jun 4 |
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
|
May 9 |
Surrozen Non-GAAP EPS of -$4.24
|
May 9 |
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
|